Interview with Ed Prideaux, Journalist at the Perception Restoration Foundation

Hello back Psychedelic Investors! In this video we are going to be entering the Speculation Zone to discuss the implications of several of MindMed’s most recent moves. Aka, we shall be Speculating on The Future of MindMed [Big News for MMED/MMEDF STOCK].

Timestamps:
0:00 – Intro
2:52 – Speculating on LSD Trials
7:44 – MindMed’s Partnership Meaning
13:45 – Nasdaq Uplisting

This is actually the second video being released today. Earlier we posted a video detailing the three most recent press releases distributed by MindMed, where we explained what each move meant. If you haven’t seen that episode yet and want to get a detailed explanation of each Press Release before watching this video speculating on that information, you should probably do that first!

Well actually, MindMed has since released another press release since the first video was filmed, on the commencement of their LSD Neutraliser phase 1 clinical trial.
In our Video on MindMed’s Latest News, we discussed:

1. How MindMed has started a phase 1 clinical trial studying the effects of mixing LSD and MDMA;
2. We examined MindMed’s changes in Leadership, where JR Rahn became the sole CEO, and a gentleman by the name of Dr. Glick left the board;
3. We also talked about MindMed’s new partnership with a company called MindShift Compounds AG, which is developing novel compounds owned exclusively by MMED.

In this video, we discuss/SPECULATE on all of MindMed’s latest changes and how some of them could potentially influence the MMED/MMEDF stock’s uplisting on NASDAQ.

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video by Pressmaster from Pexels

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMEDF #MindmedStock

The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor

Join the Psychedelic Investor and the CEOs of MindMed (Rob Barrow) and Cybin (Doug Drysdale), and the Executive Chairman of Field Trip (Ronan Levy) as they discuss the future of psychedelic medicines.

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

If you are interested in investing in psychedelic stocks, then this is the even for you. Full of knowledge and unique information, this CEO discussion is a must.

Learn about the companies behind MindMed’s stock (Nasdaq: MNMD, NEO: MMED), Cybin’s stock (NYSE: CYBN, NEO: CYBN) and Field Trip Health’s stock (Nasdaq: FTRP, TSX: FTRP).

Presented by PsychedelicSpotlight.com, this conversation is as great a starting place as any to learn about psychedelic stocks

#Psychedelics #MindMed #Investing